Nls pharmaceutics announces promising preclinical results for parkinson's disease treatments

Zurich, switzerland / accesswire / june 27, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical results from multiple in vitro studies targeting alpha-synuclein (Α-synuclein), specifically the a53t mutation, that demonstrate the compounds' potential to advance the treatment of parkinson's disease (pd).
NLSP Ratings Summary
NLSP Quant Ranking